重组人脑利钠肽治疗急性心肌梗死伴心衰患者124例临床效果观察

Recombinant human brain natriuretic peptide for acute myocardial infarction with heart failure in 124 patients

目的探讨重组人脑利钠肽治疗急性心肌梗死伴心力衰竭的临床效果。方法选取在我院治疗的急性心肌梗死伴心力衰竭患者248例，将其随机分为观察组和对照组，每组124例；对照组给予常规治疗，观察组加用重组人脑利钠肽进行治疗，比较两组效果。结果观察组总有效率为95．16％，对照组总有效率为61．29％；观察组左室射血分数（LVEF）、心脏指数（CI）和二尖瓣舒张期E峰和A峰的比值（E／A）明显高于对照组，血清N-末端脑利钠肽前体（NT—proBNP）和超敏C反应蛋白（CRP）水平明显低于对照组（P〈0．05）。结论重组人脑利钠肽用于急性心肌梗死伴心力衰竭患者的治疗，疗效好。

Objective To investigate the clinical efficacy of recombinant human brain natriuretic peptide in patients with acute myocardial infarction complicated with heart failure. Methods 248 patients with acute myocardial infarction and heart failure who had been treated in our hospital were randomly divided into study group and control group, 124 for each group. The control group received routine treatment, and the study group received recombinant human brain natriuretic peptide in addition to the routine thearpy. The efficacy was compared. Results The total effectiveness rate was 95.16% in the study group and 61.29% in the control group. LVEF, CI, and E/A were significantly higher in the study group than in the control group while levels of NT-proBNP and CRP were significantly lower （ P 〈 0.05 ）. Conclusions Recombinant human brain natriuretic peptide for acute myocardial infarction and heart failure has a better efficacy.